Market Research Outlook on Hypersensitivity - Pipeline Review, H2 2016
Hypersensitivity - Pipeline Review, H2 2016 is a new market research publication announced by Reportstack. This report provides an overview of the Hypersensitivity pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Hypersensitivity, complete with analysis by stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hypersensitivity and features dormant and discontinued projects.
Complete report available @ Hypersensitivity - Pipeline Review, H2 2016
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Scope
- The report provides a snapshot of the global therapeutic landscape of Hypersensitivity
- The report reviews pipeline therapeutics for Hypersensitivity by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report reviews key players involved Hypersensitivity therapeutics and enlists all their major and minor projects
- The report assesses Hypersensitivity therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Hypersensitivity
- The report reviews pipeline therapeutics for Hypersensitivity by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report reviews key players involved Hypersensitivity therapeutics and enlists all their major and minor projects
- The report assesses Hypersensitivity therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Hypersensitivity
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Hypersensitivity pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Hypersensitivity pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Adamis Pharmaceuticals Corporation Adverum Biotechnologies, Inc. Aimmune Therapeutics, Inc. Alfacyte Ltd ALK-Abello A/S Allakos Inc. Allergopharma GmbH & Co. KG Allergy Therapeutics Plc Amgen Inc. Anacor Pharmaceuticals, Inc. AnaptysBio, Inc. Anergis SA Antigen Express, Inc. Aravax Pty Ltd Array BioPharma Inc. ASIT biotech s.a. AskAt Inc. Astellas Pharma Inc. BioLingus AG Biomay AG Biotec Pharmacon ASA Boehringer Ingelheim GmbH Circassia Pharmaceuticals Plc DBV Technologies S.A. DNJ Pharma, Inc. EA Pharma Co Ltd Enzene Biosciences Ltd. EpiVax, Inc. Fountain Biopharma Inc. HAL Allergy BV iCeutica, Inc. ImmunoFrontier, Inc. Immunomic Therapeutics, Inc. Immupharma Plc InMed Pharmaceuticals Inc. Interprotein Corporation Japan Tobacco Inc. JW Pharmaceutical Corporation Laboratorios LETI S.L. Monosol Rx, LLC NAL Pharmaceuticals Ltd. Neovacs SA Novartis AG Ono Pharmaceutical Co., Ltd. Regeneron Pharmaceuticals Inc REGiMMUNE Corporation Roxall Medizin GmbH Sanofi Sealife PHARMA GMBH Stallergenes Greer plc Stallergenes SAS Swecure AB Therabron Therapeutics, Inc. Thesan Pharmaceuticals, Inc. Toleranzia AB United Biomedical, Inc. United BioPharma, Inc.
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
Reportstack Market Research
###
posted by Reportstack @ 07:12
0 Comments
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home